EU/3/15/1498

About

Please note that this product was withdrawn from the Union Register of orphan medicinal products in April 2020 on request of the sponsor.

On 21 May 2015, orphan designation (EU/3/15/1498) was granted by the European Commission to Clinical Network Services (UK) Ltd, United Kingdom, for 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide for the treatment of cystic fibrosis.

The sponsorship was transferred to Clinical Network Services (NL) B.V., The Netherlands, in January 2019.

Key facts

Active substance
2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide
Disease / condition
Treatment of cystic fibrosis
Date of first decision
21/05/2015
Outcome
Withdrawn
EU designation number
EU/3/15/1498

Review of designation

Please note that this product was withdrawn from the Union Register of orphan medicinal products in April 2020 on request of the sponsor.

Sponsor's contact details

Scendea (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
Noord-Holland
The Netherlands
Tel. +31 2089 49169
E-mail: orphan@scendea.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating